Pharmacokinetic Interaction Between Nevirapine and Ethinyl Estradiol/Norethindrone When Administered Concurrently to HIV-Infected Women

Mildvan, Donna; Yarrish, Robert; Marshak, Ann; Hutman, H. Wayne; McDonough, Marita; Lamson, Michael; Robinson, Patrick

doi:10.1097/00126334-200204150-00007

Cited by 53 publications

(28 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one study (6), oral ritonavir resulted in statistically significant decreases in ethinyl E 2 levels from a single dose of a contraceptive pill. In another study (7), oral nevirapine significantly reduced both ethinyl E 2 and norethindrone levels. No studies have evaluated clinical outcomes such as pregnancy, though one study did not find evidence that use of hormonal contraceptives strongly affected responses to ARV therapy (8).…”

mentioning

confidence: 89%

Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy

Nanda

Amaral

Hays

et al. 2008

Fertility and Sterility

View full text Add to dashboard Cite

mentioning

confidence: 89%

Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy

Nanda

Amaral

Hays

et al. 2008

Fertility and Sterility

View full text Add to dashboard Cite

“…Previously nevirapine was shown to decrease the AUC of EE and NE by 29% and 18%, respectively [68]. Stuart and colleagues reported conflicting findings when they found the highest concentrations of both EE and norgestrel in patients taking nevirapine vs. those not taking cART.…”

Section: Oral Contraceptivesmentioning

confidence: 98%

Important Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs

Tseng

Foisy²

2011

Curr Infect Dis Rep

View full text Add to dashboard Cite

Advances in antiretroviral therapy have turned HIV into a chronic, manageable disease. Patients often require treatment for co-morbid conditions as well as HIV, and consequently, pharmacokinetic interactions between antiretrovirals (ARVs) and other drug classes are an increasing concern. Protease inhibitors and non-nucleoside reverse transcriptase inhibitors are involved in the CYP450 or other transporter systems, and may be associated with higher risk of clinically significant drug interactions. One reverse transcriptase inhibitor, abacavir, has demonstrated weak inhibition of CYP3A4, 2D6 and 2C9 in vitro, but is not associated with any clinically significant interactions involving the CYP450 system. The integrase inhibitor raltegravir is not involved in the CYP450 system, and may be a suitable option to use when trying to minimize interactions with other drug classes. This review summarizes recently published data on clinically significant drug interactions between ARVs and other drug classes including antineoplastics, immunosuppressant transplant drugs, directly acting antivirals for hepatitis C, antifungals, antimalarials, corticosteroids, psychotropics, hormonal contraceptives, anticoagulants, drugs for pulmonary hypertension, and herbal products. In situations of suspected or potential interactions, close monitoring is warranted, and dose adjustments or substitutions may be required.

show abstract

“…Studies of interactions between oral contraceptives and ART have shown decreased levels of estrogen by 29% for some nonnucleoside reverse transcriptase inhibitors such as nevirapine (Mildvan et al, 2002), but 22% to 37% increased estrogen levels with others (i.e., efavirenz, etravirine; DHHS, 2009). Interactions between oral contraceptives and PIs (without boosted ritonavir) are also varied.…”

Section: Gender Confirming Hormones With Antiretroviral Therapymentioning

confidence: 99%

Providing Care to Transgender Persons: A Clinical Approach to Primary Care, Hormones, and HIV Management

Williamson¹

2010

Journal of the Association of Nurses in AIDS Care

View full text Add to dashboard Cite

Transgender (TG) persons have had historically difficult interactions with health care providers, leading to limited care and risks for a broad spectrum of health problems. This is of particular concern for TG persons with or at risk for HIV infection. This article discusses care providers' roles in establishing TG-friendly clinical care sites; conducting appropriate and thorough physical examinations for TG patients; managing hormones, especially in conjunction with antiretroviral therapy; and engaging TG persons in education about prevention and treatment of HIV.

show abstract

Pharmacokinetic Interaction Between Nevirapine and Ethinyl Estradiol/Norethindrone When Administered Concurrently to HIV-Infected Women

Abstract: Oral contraceptives should not be the primary method of birth control in women of child-bearing potential who are treated with NVP.

Cited by 53 publications

References 13 publications

Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy

Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy

Important Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs

Providing Care to Transgender Persons: A Clinical Approach to Primary Care, Hormones, and HIV Management

Contact Info

Product

Resources

About